Enjoy a new batch of notable scientific and medical journal articles that drove the conversation, curated from the best of the biotech enthusiasts on Twitter.
Great review here of Ph 2 & Ph 3 failures. Puts risk/reward into proper perspective! https://t.co/QRalzIF4OH— Sheff (@SheffStation) November 4, 2016
Phase II trial of nusinersen to treat infantile-onset spinal muscular atrophy produces encouraging results https://t.co/Y4AZkMQlxi— Nat Rev Neurology (@NatRevNeurol) December 7, 2016